<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00888446</url>
  </required_header>
  <id_info>
    <org_study_id>IAVI A002</org_study_id>
    <nct_id>NCT00888446</nct_id>
  </id_info>
  <brief_title>Safety and Immunogenicity Study of tgAAC09, an HIV Vaccine in an Adeno-associated Virus (AAV) Capsid</brief_title>
  <acronym>TGC14F</acronym>
  <official_title>Phase II, Placebo-controlled, Double-blind, Dose-escalation/Dose-optimization Trial to Evaluate Safety and Immunogenicity of tgAAC09, an HIV Vaccine Containing Clade C Gag-PR-ΔRT DNA in an Adeno-associated Virus (AAV) Capsid</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>International AIDS Vaccine Initiative</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Targeted Genetics Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>International AIDS Vaccine Initiative</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase 2 study will evaluate the safety, immunogenicity and optimal timing of two&#xD;
      injections at three dose levels of the tgAAC09 vaccine in healthy volunteers. Study&#xD;
      volunteers will receive two intramuscular injections of tgAAC09 or placebo at Months 0 and 6&#xD;
      (groups A, C, E and G) or at Months 0 and 12 (groups B, D and F) and be followed for a total&#xD;
      of 18 months following the first injection with the exception of group G in which volunteers&#xD;
      will be followed for 12 months after the first injection (6 months after the second&#xD;
      injection). This study will explore whether boosting is possible, and compare a shorter and&#xD;
      more practical six-month time interval with a twelve-month time interval.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study design will also assess the effect of the presence of anti-AAV2 capsid neutralizing&#xD;
      antibodies at the time of vaccination on the safety and immunogenicity of tgAAC09. Since the&#xD;
      prevalence of pre-existing neutralizing antibodies to AAV2 capsid is high (IAVI and Targeted&#xD;
      Genetics, data on file), this protocol amendment adds Group G which is composed of volunteers&#xD;
      who have documented pre-existing anti-AAV2 capsid neutralizing antibodies titers ≤ 1/8. This&#xD;
      will assure that there are sufficient numbers of volunteers with and without antibodies for a&#xD;
      useful comparison.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2005</start_date>
  <completion_date type="Actual">December 2007</completion_date>
  <primary_completion_date type="Actual">December 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety: proportion of volunteers with severe local and systemic reactions, proportion of volunteers with other SAEs (including laboratory abnormalities) related to study vaccine, number of volunteers with SAEs related to study vaccine</measure>
    <time_frame>18 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of volunteers with HIV-1 specific T- cell responses quantified by γ-IFN ELISPOT and magnitude of the response, and proportion of volunteers with HIV-1 specific binding antibodies and magnitude of the response</measure>
    <time_frame>18 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety: high versus low or negative titres of neutralizing antibodies to AAV2 at the time of each vaccination</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity: proportion of volunteers with HIV-1 specific T- cell responses by γ-IFN CFC or other T-cell assays</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity endpoints in volunteers with high versus low or negative titres of neutralizing antibodies to AAV2 at the time of each vaccination</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity endpoints in volunteers with versus without four-fold or greater increase in titres of neutralizing antibodies to AAV2 after vaccination</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity endpoints after the second study injection, compared with the first study injection</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity endpoints after the second study injection following a twelve-month interval compared to a six-month interval</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vaccine biodistribution: presence and persistence of vaccine in peripheral blood mononuclear cells (PBMC), saliva, nasal swabs, urine and semen or cervical/vaginal secretions</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Actual">91</enrollment>
  <condition>Human Immunodeficiency Virus Infections</condition>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Number of Vaccine Recipients: 10&#xD;
Dosage level 3 x 10^10 DRP&#xD;
Month 0 + 6</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Number of Vaccine Recipients: 10&#xD;
Dosage level 3 x 10^10 DRP&#xD;
Month 0+12</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Number of Vaccine Recipients: 10&#xD;
Dosage level 3 x 10^11 DRP&#xD;
Month 0+6</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Number of Vaccine Recipients: 10&#xD;
Dosage level 3 x 10^11 DRP&#xD;
Month 0+12</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group E</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Number of Vaccine Recipients: 10&#xD;
Dosage level 3 x 10^12 DRP&#xD;
Month 0+6</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group F</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Number of Vaccine Recipients: 10&#xD;
Dosage level 3 x 10^12 DRP&#xD;
Month 0+12</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group G</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Number of Vaccine Recipients: 10&#xD;
Preselected for baseline AAV neutralization titers of &lt;1/8&#xD;
Dosage level 3 x 10^12 DRP&#xD;
Month 0+6</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>3 volunteers will receive placebo matched to each experimental group.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>tgAAC09</intervention_name>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_label>Group B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>tgAAC09</intervention_name>
    <arm_group_label>Group C</arm_group_label>
    <arm_group_label>Group D</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>tgAAC09</intervention_name>
    <arm_group_label>Group E</arm_group_label>
    <arm_group_label>Group F</arm_group_label>
    <arm_group_label>Group G</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Formulation buffer</intervention_name>
    <description>Sterile isotonic buffered salt solution</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy male or female&#xD;
&#xD;
          -  Age at least 18 years on the day of screening and no greater than 50 years on the day&#xD;
             of the first study injection&#xD;
&#xD;
          -  Willing to comply with the requirements of the protocol and available for follow up&#xD;
             for the planned duration of the study&#xD;
&#xD;
          -  Able and willing to give informed consent.&#xD;
&#xD;
          -  Willing to undergo HIV testing, counseling and receive results&#xD;
&#xD;
          -  If sexually active female of child-bearing potential (not menopausal or anatomically&#xD;
             sterile), willing to use an effective method of contraception (hormonal&#xD;
             contraceptives; intrauterine contraceptive device (IUCD); condoms; anatomical&#xD;
             sterility in self or partner) from screening until at least four months after last&#xD;
             study injection and willing to undergo urine pregnancy tests at screening, prior to&#xD;
             each injection and four months after the last injection&#xD;
&#xD;
          -  If sexually active male, willing to use a method of contraception (such as condoms)&#xD;
             from screening until four months after the last study injection&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  HIV-1 or HIV-2 infection&#xD;
&#xD;
          -  Active tuberculosis&#xD;
&#xD;
          -  Clinically relevant abnormality on history or examination including history of&#xD;
             immunodeficiency, or cancer, or autoimmune disorder&#xD;
&#xD;
          -  Use of systemic corticosteroids, immunosuppressive or anticancer medications in the&#xD;
             last six months&#xD;
&#xD;
          -  Chronic condition that, in the opinion of the investigator or the designated trial&#xD;
             physician, would make the volunteer unsuitable for the study&#xD;
&#xD;
          -  Any of the following abnormal laboratory parameters:&#xD;
&#xD;
               -  Hemoglobin &lt;9.0 g/dL (females), &lt;12.0 g/dL (males)&#xD;
&#xD;
               -  Absolute Neutrophil Count (ANC): ≤ 999/mm3&#xD;
&#xD;
               -  Absolute Lymphocyte Count (ALC): ≤ 500/mm3&#xD;
&#xD;
               -  Platelets: decreased ≤ 90,000 or increased ≥ 550,000/mm3&#xD;
&#xD;
               -  Creatinine: &gt; 1.4 x ULN&#xD;
&#xD;
               -  AST: &gt;3.0 x ULN&#xD;
&#xD;
               -  ALT: &gt;3.0 x ULN&#xD;
&#xD;
               -  Urine dipstick: blood = 2+ or more (except in menstruating females); protein = 2+&#xD;
                  or more&#xD;
&#xD;
          -  Any of the following high-risk behaviors:&#xD;
&#xD;
               -  Had unprotected vaginal or anal sex with a known HIV positive person in the past&#xD;
                  six months&#xD;
&#xD;
               -  Had unprotected vaginal or anal sex with a casual partner (i.e. no continuing&#xD;
                  established relationship) in the past six months&#xD;
&#xD;
               -  Engaged in sex work for money or drugs in the past six months&#xD;
&#xD;
               -  Used injection drugs illegally in the past six months&#xD;
&#xD;
               -  Acquired a sexually transmitted infection (STI) in the past six months&#xD;
&#xD;
          -  If female, pregnant, lactating or planning a pregnancy within four months after last&#xD;
             study injection&#xD;
&#xD;
          -  Receipt of live attenuated vaccine within 30 days or other vaccine within 14 days of&#xD;
             the first study injection&#xD;
&#xD;
          -  Receipt of blood transfusion or blood products six months prior to the first study&#xD;
             injection&#xD;
&#xD;
          -  Participation in another clinical trial of an investigational product currently or&#xD;
             within last 12 weeks of first study injection or expected participation during this&#xD;
             study&#xD;
&#xD;
          -  Prior receipt of an investigational HIV vaccine&#xD;
&#xD;
          -  History of severe local or systemic reaction to vaccination(s) or history of severe&#xD;
             allergic reactions&#xD;
&#xD;
          -  History of major neurological or psychiatric disorders&#xD;
&#xD;
          -  Positive for hepatitis B surface antigen, active untreated syphilis (confirmed by&#xD;
             treponemal test such as TPHA in addition to nontreponemal test such as RPR) or other&#xD;
             active sexually transmitted diseases&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eftyhia Vardas, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Perinatal HIV Research Unit (PHRU), Baragwanath</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Linda-Gail Bekker, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Desmond Tutu HIV Centre Cape Town</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Anwar Hoosen</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of Southern Africa (Medunsa)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Elwyn Chomba, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Zambia-Emory HIV Research Project (ZEHRP), Lusaka</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Pontiano Kaleebu, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>MRC/UVRI and LSHTM Uganda Research Unit</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Desmond Tutu HIV Centre Cape Town</name>
      <address>
        <city>Cape Town</city>
        <zip>7920</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medunsa</name>
      <address>
        <city>South Africa</city>
        <zip>0204</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Perinatal HIV Research Unit, Baragwanath Hospital</name>
      <address>
        <city>Soweto</city>
        <zip>2013</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uganda Virus Research Institute</name>
      <address>
        <city>Entebbe</city>
        <country>Uganda</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zambia-Emory HIV Research Project (ZEHRP)</name>
      <address>
        <city>Lusaka</city>
        <country>Zambia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>South Africa</country>
    <country>Uganda</country>
    <country>Zambia</country>
  </location_countries>
  <link>
    <url>http://www.iavi.org</url>
    <description>Related Info</description>
  </link>
  <results_reference>
    <citation>Vardas E, Kaleebu P, Bekker LG, Hoosen A, Chomba E, Johnson PR, Anklesaria P, Birungi J, Barin B, Boaz M, Cox J, Lehrman J, Stevens G, Gilmour J, Tarragona T, Hayes P, Lowenbein S, Kizito E, Fast P, Heald AE, Schmidt C. A phase 2 study to evaluate the safety and immunogenicity of a recombinant HIV type 1 vaccine based on adeno-associated virus. AIDS Res Hum Retroviruses. 2010 Aug;26(8):933-42. doi: 10.1089/aid.2009.0242.</citation>
    <PMID>20666584</PMID>
  </results_reference>
  <verification_date>December 2012</verification_date>
  <study_first_submitted>April 23, 2009</study_first_submitted>
  <study_first_submitted_qc>April 24, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 27, 2009</study_first_posted>
  <last_update_submitted>December 13, 2012</last_update_submitted>
  <last_update_submitted_qc>December 13, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 17, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HIV</keyword>
  <keyword>HIV seronegativity</keyword>
  <keyword>preventative vaccine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

